Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients

Lung Cancer. 2017 Feb:104:131-133. doi: 10.1016/j.lungcan.2016.11.007. Epub 2016 Nov 11.

Authors

Oscar Juan¹, Sanjay Popat²

Affiliations

¹ Department of Medical Oncology, Hospital Universitari i Politècnic La FE, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain. Electronic address: juan_osc@gva.es.
² Lung Unit, Royal Marsden Hospital, London SW3 6JJ, UK; National Heart & Lung Institute, Faculty of Medicine, Imperial College London, Guy Scadding Building, Cale Street, London SW3 6LY, UK; The Institute of Cancer Research, 123 Old Brompton Road, London SW7 3RP, UK.

PMID: 27863911
DOI: 10.1016/j.lungcan.2016.11.007

No abstract available

Keywords: Crizotinib; Non-small cell lung cancer; ROS1 fusions; Targeted therapy.

Publication types

Editorial

MeSH terms

Biomarkers, Tumor*
Carcinoma, Non-Small-Cell Lung / diagnosis*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / mortality
Crizotinib
Genetic Testing
Humans
Lung Neoplasms / diagnosis*
Lung Neoplasms / drug therapy*
Lung Neoplasms / mortality
Molecular Targeted Therapy
Neoplasm Staging
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / genetics*
Protein-Tyrosine Kinases / metabolism
Proto-Oncogene Proteins / genetics*
Proto-Oncogene Proteins / metabolism
Pyrazoles / therapeutic use*
Pyridines / therapeutic use*
Treatment Outcome

Substances

Biomarkers, Tumor
Protein Kinase Inhibitors
Proto-Oncogene Proteins
Pyrazoles
Pyridines
Crizotinib
Protein-Tyrosine Kinases
ROS1 protein, human